Status:
RECRUITING
ctDNA Monitoring in Early Breast Cancer
Lead Sponsor:
Geneplus-Beijing Co. Ltd.
Collaborating Sponsors:
Army Medical University, China
Conditions:
Breast Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of c...
Eligibility Criteria
Inclusion
- Patients aged 18 to 80 years old
- Histologically proven primary breast cancer with clinical stage I-III
- Patients with neoadjuvant therapy, and/or radical surgery/breast conserving surgery, adjuvant chemotherapy and target therapy (Her2+), radiotherapy (if indicated).
- Expected to achieve R0 resection.
- Estimated lifetime is more than 3 months.
- Signed Informed Consent Form
- Consent to provide research blood samples.
Exclusion
- Patients intended to receive adjuvant chemotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 3, 4 or 5.
- Patients intended to receive postoperative radiotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 5.
- Prior diagnosis of cancer in the previous 5 years, other than for basal cell carcinoma of the skin or cervical carcinoma in situ.
- Presence of any systemic illness incompatible with participation in the clinical trial or inability to provide written informed consent.
Key Trial Info
Start Date :
November 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04353557
Start Date
November 29 2019
End Date
December 1 2026
Last Update
July 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Army Medical Center of PLA, China
Chongqing, Chongqing Municipality, China, 400042